Source comparison
Comparison Table: Tesamorelin vs Other Peptides and GH Interventions
Anti-aging practitioners often evaluate tesamorelin alongside other growth hormone-modulating compounds. This table compares key characteristics: Tesamorelin GHRH analog. Stimulates pituitary GH release 15–18% reduction in 26 weeks (clinical trial data) 30–50%
This comparison does not assign a generated winner or score.
- Anti-aging practitioners often evaluate tesamorelin alongside other growth hormone-modulating compounds. This table compares key characteristics:
- Tesamorelin
- GHRH analog. Stimulates pituitary GH release
- 15–18% reduction in 26 weeks (clinical trial data)
- 30–50% increase from baseline
- 2mg daily subcutaneous injection
- FDA-approved with strongest clinical evidence for visceral fat targeting. Gold standard for metabolic optimization protocols
- CJC-1295 (modified GRF 1-29)
- GHRH analog with extended half-life
- Limited published data. Anecdotal reports only
- Variable. Dose-dependent
- 1–2mg weekly subcutaneous injection
- Not FDA-approved. Lacks Phase III trial data; mechanism similar to tesamorelin but without regulatory oversight or standardized dosing
- Exogenous GH (somatropin)
- Direct GH replacement
- Effective but non-specific. Reduces subcutaneous and visceral fat
- 200–300% increase (supraphysiological)
- Daily subcutaneous injection (dose varies)
- Potent but high side-effect profile (edema, joint pain, insulin resistance); suppresses endogenous GH axis; typically reserved for diagnosed GH deficiency
- MK-677 (ibutamoren)
- Ghrelin mimetic. Stimulates GH and prolactin
- Minimal visceral fat effect in published trials
- 30–60% increase from baseline
- 25mg daily oral
- Oral bioavailability is convenient but also raises prolactin and cortisol; appetite stimulation complicates body composition goals
- Sermorelin
- GHRH analog (shorter half-life than tesamorelin)
- Limited published data on visceral fat
- 20–40% increase from baseline
- Daily subcutaneous injection
- Similar mechanism to tesamorelin but shorter duration of action requires more frequent dosing; less clinical trial support